Sequences of Aerobic and Resistance Exercise in Training and Their Effects on Cardio-metabolic Functions Among Type 2 Diabetes Patients - a Randomized Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 56
- Locations
- 1
- Primary Endpoint
- Fasting Glucose at Baseline
Study Overview
Brief Summary
Aerobic exercise and resistance exercise are two types of exercise commonly used in physical conditioning. Compared to aerobic exercise, a combination of aerobic and resistance exercise has been linked to a greater reduction in hemoglobin A1c (HbA1c) among patients with type 2 diabetes (T2D). However, it is not clear that in a concurrent aerobic-resistance training session, whether the orders of the two types of exercise could act differently in glucose metabolism. This randomized trial aims to investigate the effect of the sequence of exercise modalities (aerobic-resistance vs resistance-aerobic in a training session) on glycemic control among T2D patients following an 8-wk intervention period.
Detailed Description
Objectives:
This randomized study aims to explore the effects of aerobic and resistance training sequences on glycemic control among type 2 diabetes (T2D) patients through an 8-wk combined aerobic and resistance exercise training program.
Study Population:
A total of 56 participants with T2D aged 50-70 years (sex ratio approximately 1:1) with a course of type 2 diabetes of more than one year are included. Participants are residents of Nanjing Municipality, Jiangsu Province, China. Participants are recruited from the outpatients at Maigaoqiao Community Health Service Center, Qixia District, Nanjing, China or through online advertisement published on the official social media (WeChat) channels of the Health Service Center.
Randomization:
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 50 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 50-70 years;
- •Type 2 diabetes diagnosed as: random blood glucose ≥11.1mmol/L (200mg/dL) or fasting blood glucose ≥7.0mmol/L (126mg/L) or oral glucose tolerance test (2h) ≥11.1mmol/L (200mg/dL) or glycated hemoglobin (HbA1c) ≥ 6.5%;
- •The course of type 2 diabetes lasted for one year or longer;
- •Willing to participate and sign the informed consent form voluntarily
Exclusion Criteria
- •Type 1 diabetes;
- •Fasting blood glucose (FBG)>16.7mmol/L;
- •Severe complications of diabetes such as acute infection, diabetic ketoacidosis, and plantar lesions;
- •Severe kidney disease, cardiovascular and cerebrovascular diseases as identified by a specialist;
- •Musculoskeletal, neurological, psychiatric or other disorders which limit the ability to exercise as identified by a specialist;
- •Doing physical exercise regularly (≥ 3 times per week, at least 1 hour per session of moderate to vigorous activities);
- •Currently under dietary program for weight loss;
- •Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at rest;
- •Abnormal electrocardiogram (rest and exercise);
- •Other comorbidities or medications irrelevant to diabetes treatment that may influence glycemia during the past 6 months
Arms & Interventions
AR group
aerobic exercise then resistance exercise in all training sessions
Intervention: AR group: aerobic training before resistance training (Behavioral)
RA group
resistance exercise then aerobic exercise in all training sessions
Intervention: RA group: resistance exercise before aerobic exercise (Behavioral)
Outcomes
Primary Outcomes
Fasting Glucose at Baseline
Time Frame: At week 0, within 7 days before the intervention starts
blood glucose level following overnight (12-h) fasting
Fasting Glucose at Follow-up
Time Frame: At week 9, within 7 days after the intervention completes
blood glucose level following overnight (12-h) fasting
Hemoglobin A1c (HbA1c) at Baseline
Time Frame: At baseline, within 7 days before the intervention starts
At baseline, the HbA1c level in blood among all participants
Hemoglobin A1c (HbA1c) at Follow-up
Time Frame: At week 9, within 7 days after the completion of the 8-week intervention
After intervention, the HbA1c level in blood among all participants
Continuous Glucose Monitoring at Baseline (Mean, sd, Lage)
Time Frame: At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (mean, sd, lage)
At baseline, 14-day continuous glucose monitoring including mean, sd, cv, lage, tir, tar, tbr
Continuous Glucose Monitoring at Baseline (Coefficient of Variation)
Time Frame: At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (cv)
At baseline, 14-day continuous glucose monitoring including mean glucose value, standard deviation (SD) of the glucose values, coefficient of variation (CV) of relative standard deviation, LAGE, TIR, TAR, TBR
Continuous Glucose Monitoring at Baseline (Tir, Tar, Tbr)
Time Frame: At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (tir, tar, tbr)
At baseline, 14-day continuous glucose monitoring including mean, sd, cv, lage, tir, tar, tbr
Continuous Glucose Monitoring at Follow-up (Mean, sd, Lage)
Time Frame: at week 8-9
After intervention, 14-day continuous glucose monitoring including mean, sd, cv, lage, tir, tar, tbr
Continuous Glucose Monitoring at Follow-up (Coefficient of Variation)
Time Frame: at week 8-9
At baseline, 14-day continuous glucose monitoring including mean glucose value, standard deviation (SD) of the glucose values, coefficient of variation (CV) of relative standard deviation, LAGE, TIR, TAR, TBR
Continuous Glucose Monitoring at Follow-up (Tir, Tar, Tbr)
Time Frame: at week 8-9
After intervention, 14-day continuous glucose monitoring including mean, sd, cv, lage, tir, tar, tbr
Secondary Outcomes
No secondary outcomes reported
Investigators
Xiao Tan
Associate Professor
Zhejiang University